Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by Eoganachton Sep 29, 2020 1:28pm

131 Views

Post# 31635787

RE:RE:RE:9 months data point

I agree 100%. The pandemic and the procedural blunder have made things look far worse than they really are. In my opinion we are just experiencing a temporary delay in what will be a very successful trial.

enriquesuave wrote:
I agree Eoganacht, Radachlorin had 90% CR at 12 months and over 60% at 24 months with 2-3 treatments and those results were similar for both HG T1 papillary and CIS. That's why I believe we can achieve between 60-90% CR at 12 months and be a safer and instilled drug versus IV. Like I said before we were even lucky to get 25% CR given that the patient who got the best treatment was still undertreated by 39% and the one who got the worst was undertreated by 154% for an average under treatment of 75%. 25% power gave 25% CR. Let's use 110% power and get 110% CR. please. For PDT to be effective full dose must be given and it will show consistent results. It's a One time SIMPLE treatment ( 2nd time 6 months later) that must be done properly 1)Proper drug dose and 2) Maximum bladder volume expansion during treatment to ensure both that 1) entire bladder surface had enough drug contact and 2) entire bladder Urothelium was exposed to green light. Simple but both rely on using Maximum bladder volume. If this was not done, then we can say they only treated 25% of bladder surfaces and 75% were not treated. What do you expect? Next batch will definitely prove this once and for all just hope they get it right. All ImO

Eoganacht wrote: Yes. For what it's worth, I think results are still going to be spectacular. The currently deflated stock price does not reflect the actual prospects of the trial.

It's good to remember that photofrin achieved a CR rate of 50-80% at 2-3 months and 20-60% at 1-2 years. TLD1433 is a far superior pdc than photofrin in both efficacy and safety and we can expect the CR rates for TLD1433 to be much higher than photofrin.

Now that the bladder volume screw up is behind us...

enriquesuave wrote: Given the screw up in bladder volume, it would be nice and comforting for us shareholders and the market, that the company provide an update at 9 months mark for first batch of 12 patients. That would be 3 months after each got 2nd treatment. At least 4 of 7 would have gotten optimized 2nd treatment. That may set the tone for what is to come for 2nd batch and help SP significantly. All IMO. We deserve it.